MAIA Biotechnology (MAIA) vs PDS Biotechnology (PDSB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PDS Biotechnology (PDSB) has outperformed MAIA Biotechnology (MAIA) over the past year, gaining 2.0% versus a loss of 36.5%. PDS Biotechnology is the larger company by market cap ($73.9 million vs $71.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MAIA | PDSB |
|---|---|---|
| Share price | $1.15 | $1.02 |
| Market cap | $71.00M | $73.92M |
| 1-day change | -2.54% | -4.23% |
| YTD return | -24.84% | +32.47% |
| 1-year return | -36.46% | +2.00% |
| 5-year return | — | -91.73% |
| Forward P/E | 1.04 | — |
| EPS (TTM) | $-0.62 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.19 | $1.55 |
| 52-week low | $0.87 | $0.195 |
| Distance from 52-week high | -63.95% | -34.19% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +943.48% | +390.20% |
| Average volume | 527.89K | 23.24M |
| Shares outstanding | 61.74M | 72.47M |
| Employees | 13 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PDSB has outperformed MAIA by 38.5 percentage points over the past year.
About MAIA Biotechnology
MAIA stock →MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC).
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
MAIA vs PDSB FAQ
Which is bigger, MAIA Biotechnology or PDS Biotechnology?
PDS Biotechnology (PDSB) is larger, with a market capitalization of $73.92M compared with $71.00M for MAIA Biotechnology (MAIA).
Which stock has performed better over the past year, MAIA or PDSB?
PDSB returned +2.00% over the past 12 months, compared with -36.46% for MAIA (price return, excluding dividends). Past performance does not predict future results.
Are MAIA Biotechnology and PDS Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.